Company intelligence / Profile preview

Kiadis Pharma

Amsterdam, North Holland, Netherlandssanofi.com ↗

Ownership: Private
Employees: ~41
Development stage: Phase 2

Overview

Kiadis was developing innovative cell-based medicines based on their proprietary NK cell platform. Their lead product candidate was discontinued in 2019, after which they reorganized to focus solely on their NK-cell platform obtained through the acquisition of Cytosen Therapeutics[1].

Therapeutic areas: HematologyRare Diseases
Modalities: Cell-based therapiesNK cell therapeutics
Industry: Biotech

Drug pipeline

4 assets

K-NK002

Phase 2

Indications: Acute myeloid leukemia, Myelodysplastic syndrome

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kiadis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kiadis Pharma.

Explore the full profile